Berlin, 3 March 2021 – The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people...
Phase I trial to assess safety, tolerability and pharmacokinetics of AC102-suspension after application into the middle ear of healthy volunteers Milestone achievement for AudioCure Pharma on its way to combating hearing loss disorders with unmet medical need Berlin,...
AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...
The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural...
We are very happy to announce that we have expanded our team with further experts for formal preclinical and clinical development to propel our way into the clinical stage with our disease modifying lead compound AC102. AudioCure has gained the support of highly...
Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Rommelspacher will continue as CSO. AudioCure recently secured funding of about 9 million euros in a Series A financing round from Austrian MED-EL Elektromedizinische...
